ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0499

Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis
Abstract Number: 0500

T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis
Abstract Number: 0501

Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia
Abstract Number: 0502

The Effect of Osteoporosis on Developing Vertebral Compression Fracture After Single-level Posterior Lumbar Fusion Surgery: A Large Healthcare Claims Database Study
Abstract Number: 0503

The Effect of Social Isolation on 1-Year Outcomes After Surgical Repair of Low Trauma Hip Fracture
Abstract Number: 0504

Three-dimensional Ground Reaction Force Symmetry Metrics Largely Fail to Explain Cartilage Worsening in the Contralateral Knee in Persons with Unilateral Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 0505

Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis
Abstract Number: 0506

Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Abstract Number: 0507

Gut Microbe Metabolite Short-Chain Fatty Acids May Associate with Development of Respiratory Involvement in Patients with Relapsing Polychondritis
Abstract Number: 0508

Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Abstract Number: 0509

Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
Abstract Number: 0510

MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 0511

SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Abstract Number: 0512

Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis
Abstract Number: 0513

The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].